KQB198

Phase 2Small molecule

KKumquat Biosciences Inc.

KQB198 is one of 2 small molecule programs targeting GIST - Gastrointestinal Stromal Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GIST - Gastrointestinal Stromal TumorRecruiting

GIST - Gastrointestinal Stromal TumorPhase 2

Recruiting

Competition

Competitive Landscape

1 competitor in GIST - Gastrointestinal Stromal Tumor

#DrugCompanyPhaseTrials

Gleevec

Novartis

Phase 2

1 2

KQB198

KKumquat Biosciences Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Advanced Solid Malignancies

NCT06507306

Phase 1Active, not recruiting

Advanced Hematologic Malignancies

NCT06645886

Q4 2028

Phase 2Recruiting

GIST - Gastrointestinal Stromal Tumor

NCT07406633

Clinical

Trials by Indication[1]

Advanced Solid Malignancies1 trial

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Recruiting·KKumquat Biosciences Inc.·Phase 1·NCT06507306·100 enrolled

Advanced Hematologic Malignancies1 trial

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies

Active, not recruiting·KKumquat Biosciences Inc.·Phase 1·NCT06645886·13 enrolled

GIST - Gastrointestinal Stromal Tumor1 trial

A Phase 2, Multicenter, Study Evaluating the Efficacy, Safety, Tolerability, Pharmacokinetics of KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GI Stromal Tumor in 1st Line Setting

Recruiting·KKumquat Biosciences Inc.·Phase 2·NCT07406633·46 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for KQB198. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KQB198 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KQB198. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kumquat Biosciences Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: KKumquat Biosciences Inc.

KQB198

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2028

Trials by Indication[1]

Advanced Solid Malignancies1 trial

Advanced Hematologic Malignancies1 trial

GIST - Gastrointestinal Stromal Tumor1 trial

References

Drug Info

Quick Facts

Related News